sb 211475 has been researched along with Cardiovascular Stroke in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunvand, H; Feuerstein, GZ; Liu, G; Ma, XL; Ruffolo, RR; Yue, TL | 1 |
1 other study(ies) available for sb 211475 and Cardiovascular Stroke
| Article | Year |
|---|---|
SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Hemodynamics; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Peroxidase; Propanolamines; Rabbits | 1998 |